Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

NCT03232073 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
877
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Actelion